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Cardiorenal Syndrome Type 1
Pathophysiological Crosstalk Leading to Combined Heart and Kidney
Dysfunction in the Setting of Acutely Decompensated Heart Failure
Claudio Ronco, MD,*† Mariantonietta Cicoira, MD,‡ Peter A. McCullough, MD, MPH§¶#
Vicenza and Verona, Italy; and Warren, Southfield, Detroit, and Novi, Michigan
Cardiorenal syndrome (CRS) type 1 is characterized as the development of acute kidney injury (AKI) and dysfunc-
tion in the patient with acute cardiac illness, most commonly acute decompensated heart failure (ADHF). There
is evidence in the literature supporting multiple pathophysiological mechanisms operating simultaneously and
sequentially to result in the clinical syndrome characterized by a rise in serum creatinine, oliguria, diuretic resis-
tance, and in many cases, worsening of ADHF symptoms. The milieu of chronic kidney disease has associated
factors including obesity, cachexia, hypertension, diabetes, proteinuria, uremic solute retention, anemia, and
repeated subclinical AKI events all work to escalate individual risk of CRS in the setting of ADHF. All of these
conditions have been linked to cardiac and renal fibrosis. In the hospitalized patient, hemodynamic changes
leading to venous renal congestion, neurohormonal activation, hypothalamic-pituitary stress reaction, inflamma-
tion and immune cell signaling, systemic endotoxemic exposure from the gut, superimposed infection, and iatro-
genesis all contribute to CRS type 1. The final common pathway of bidirectional organ injury appears to be cellu-
lar, tissue, and systemic oxidative stress that exacerbate organ function. This review explores in detail the
pathophysiological pathways that put a patient at risk and then effectuate the vicious cycle now recognized as
CRS type 1. (J Am Coll Cardiol 2012;60:1031–42) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.077Combined disorders of heart and kidney are today classified
as cardiorenal syndromes (CRS) (1). The most recent
definition includes a variety of conditions, either acute or
chronic, where the primary failing organ can be either the
heart or the kidney. CRS are thus disorders of the heart and
kidneys whereby acute or chronic dysfunction in one organ
may induce acute or chronic dysfunction of the other. The
current definition has been expanded into 5 subtypes whose
etymology reflects the primary and secondary pathology, the
time frame, and simultaneous cardiac and renal co-dysfunction
secondary to systemic disease. Such advances in the recognition
and classification of CRS provide a platform to examine
complex organ crosstalk and introduce the possibilities of new
prevention, treatment, and recovery strategies (2). It should be
mentioned that the temporal sequence of organ dysfunction
largely distinguishes type 1 (cardiac first) from type 3 (renal
first). However, it is not only the timing, but also the
predominance of the problem that allows the correct determi-
nation. For instance, in a patient with known heart failure
(HF) who presents with acute decompensated HF (ADHF)
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baseline and then develops acute kidney injury (AKI) with the
temporary need for dialysis would be classified as type 1 CRS
since the HF was the initial, predominant problem and the
renal failure ensued.
Type 1 CRS (acute CRS) occurs in approximately 25% to
33% of patients admitted with ADHF, depending on the
criteria used, and represents an important consequence of
hospitalization with a myriad of implications for diagnosis,
prognosis, and management (3,4). There are direct and
indirect effects of HF that can be identified as the primers
for AKI and dysfunction. Factors beyond the classic hemo-
dynamic mechanisms appear to play a role in the pathogen-
esis of renal injury. Venous congestion, sympathetic nervous
system dysfunction, anemia, activation of the renin-
angiotensin aldosterone system (RAAS), disruption of the
hypothalamic-pituitary axis, and a marked alteration of im-
mune and somatic cell signaling have all been implicated. The
complexity of this syndrome presents a key challenge for
singular diagnostic or treatment approaches. Considering the
possibilities for any given patient, there are 4 subtypes of type 1
CRS: 1) de novo cardiac injury leads to de novo kidney injury;
2) de novo cardiac injury leads to acute-on-chronic kidney
injury; 3) acute-on-chronic cardiac decompensation leads to de
novo kidney injury; and 4) acute-on-chronic cardiac decom-
pensation leads to acute-on-chronic kidney injury. In this
review, we characterize in detail the nature of CRS type 1; we
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logical pathways and reconcile
mechanistic aspects of organ dam-
age into a comprehensive and ho-
listic approach to understanding
this syndrome.
Type 1 CRS is characterized by
an acute heart disorder leading to
AKI (Fig. 1) and occurs in 25%
of unselected patients admitted
with ADHF (5,6). Among these
patients, pre-morbid chronic kid-
ney disease (CKD) is common and
predisposes to AKI in approxi-
mately 60% of cases. AKI is an
independent risk factor for 1-year
mortality in ADHF patients, in-
cluding patients with ST-segment elevation myocardial infarc-
tion who develop signs and symptoms of HF or have a reduced
left ventricular ejection fraction (7). This independent effect
Abbreviations
and Acronyms
ADHF  acute
decompensated heart
failure
AKI  acute kidney injury
CRS  cardiorenal
syndrome
CKD  chronic kidney
disease
DM  diabetes mellitus
HF  heart failure
IL  interleukin
RAAS  renin-angiotensin-
aldosterone system
Figure 1 Pathogenesis of Type 1 CRS
Acute decompensated heart failure (ADHF) via arterial underfilling and venous con
factors that culminate in acute kidney injury (AKI). CKD  chronic kidney disease;might be due to an associated acceleration in cardiovascular
pathobiology due to kidney dysfunction through the activa-
tion of neurohormonal, cell signaling, oxidative stress, or
exuberant repair (fibrosis) pathways. Upon initial recogni-
tion, AKI induced by primary cardiac dysfunction implies
inadequate renal perfusion until proven otherwise (8). This
hould prompt clinicians to consider the diagnosis of a low
ardiac output state and/or marked increase in venous pressure
eading to kidney congestion. It is important to remember that
entral venous pressure translated to the renal veins is a product
f right heart function, blood volume, and venous capacitance,
hich is largely regulated by neurohormonal systems. Specific
egulatory and counter-regulatory mechanisms are activated
ith variable effects, depending on the duration and the
ntensity of the insult.
redisposition for Cardiorenal Syndromes
besity and cardiometabolic changes. There are a host of
redisposing factors that create baseline risk for CRS type 1,
sets off a series of changes in neurohormonal and hemodynamic
cardiorenal syndrome; RAAS  renin-angiotensin-aldosterone system.gestion
CRS 
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shown in Figure 2. Thus, there are developing obesity-
associated epidemics of at least 26 chronic diseases, includ-
ing type 2 diabetes mellitus (DM), hypertension, obstructive
sleep apnea, atrial fibrillation, HF, hyperuricemia, and
CKD, all directly or indirectly related to excess adiposity. It
has been shown that the number of adipocytes in the human
body can increase 10-fold both in number and in size. The
adipocytes secrete cytokines, and as a result, these cytokines
may cause cardiac and renal injury, as for example interleu-
kin (IL)-6 and tumor necrosis-factor alpha, which are both
secreted by adipocytes have been implicated in both heart
and kidney disease. Indeed, the production of IL-6 by
abdominal adipocytes into the portal circulation and transit
to the liver is the most important stimulus for release of
high-sensitivity C-reactive protein. Thus, high-sensitivity
C-reactive protein levels are highest in obese individuals and
fall to a greater extent with weight loss than any other
intervention (9,10).
Figure 2 Predisposing Factors for CRS
Obesity and cardiometabolic changes in the cardiovascular system, including diab
hormonal changes due to bone and mineral disorder, proteinuria, uremic solute re
(CRS) type 1. The course of this syndrome can lead to permanent renal failure an
filtration rate.Body mass index, a global measure of excess adiposity, is
associated with abnormalities on echocardiography, includ-
ing left atrial dilation, left ventricular hypertrophy and
dilation, and impaired relaxation (11). These findings sug-
gest that changes in the lipid content within cardiomyocytes
themselves are playing a role in these pathological steps of
cardiac remodeling.
Obesity-related glomerulopathy has been long described
as a condition of hyperfiltration in obese individuals without
DM that ultimately leads to CKD and predisposes to CRS
type 1 (12,13). In addition, the cardiometabolic syndrome
in the absence of frank DM has been associated with 3- to
7-fold increased risk of CRS type 1 in a variety of clinical
settings (14).
Cachexia. Opposite to obesity and metabolic syndromes,
combined disorders of the heart and kidney are also likely to
develop in the presence of some degree of cachexia and
sarcopenia and are associated with organ crosstalk via tumor
necrosis factor-alpha and other pro-inflammatory cytokines
nd hypertension, and later in the course of disease, cachexia, biochemical, and
, and anemia, all contribute to the risk for developing cardiorenal syndrome
for dialysis or partial renal recovery. EPO  erythropoietin; GFR  glomerularetes a
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which cachexia and nutritional deficiencies associated with
either HF or CKD may contribute to further damage and
fibrosis of the other organ (16,17). Thus, we speculate that the
occurrence of chronic CRS and cachexia could be a harbinger
of serious complications such as infection or death.
Hypertension and diabetes. Hypertension and type 2 DM
account for the majority of CKD and end-stage renal
disease in developed countries (18). Lack of blood pressure
control is directly related to accelerated loss of nephrons and
reductions in glomerular filtration rate (19). Diabetes,
through many mechanisms, contributes to glomerular dys-
function, damage, and ultimate loss of functioning filtration
units, and further contributes to CKD. Increased blood
pressure upon initial evaluation, probably as a reflection of
neurohormonal activation and sodium retention, in patients
with ADHF has been consistently associated with CRS type 1
(20). Conversely, in the setting of hypotension and shock, there is
a massive elevation of catecholamines and a failure of the heart to
respond with an increase in cardiac output. This latter scenario
accounts for 2% of type 1 CRS.
Proteinuria. Endothelial, mesangial, and podocyte injury
n the presence of hypertension and DM results in excess
uantities of albumin in Bowman’s space; thus, the proximal
ubular cells have an increased workload of reabsorption. This
henomenon has been suggested to lead to apoptosis of renal
ubular cells, further nephron loss, and progression of kidney
isease. Indeed, albuminuria and gross proteinuria has been
onsistently associated with the risk of AKI in a variety of
ettings (21). Albuminuria in the general population is predic-
ive of the development of HF, and in those with established
F, it is present in 30% and associated with hospitalization
and mortality (22,23). Microalbuminuria, thus, is a risk marker
for cardiovascular disease and CKD, and is probably a patho-
genic factor in the progression of CKD.
Uremic solute retention. Studies have demonstrated that
uremia causes myocyte dysfunction manifested by impaired
movement of calcium in the cytosol leading to impaired
contraction of myocyte elements (24). In addition, uremia
directly contributes to accelerated fibrosis and adverse car-
diac remodeling after myocardial infarction (25). Relief of
chronic uremia with renal transplantation has been associ-
ated with many changes, including improvement in left
ventricular systolic function, reduction in left ventricular
mass, and reduction in left ventricular size. Hyperuricemia
is associated with uremia and has been associated with
atherosclerosis and cardiovascular death in multiple studies
(26,27). Observational studies of patients with gout and HF
have shown that allopurinol is associated with improved
outcomes (28). Small randomized trials suggest that lower-
ing uric acid may influence the natural history and symp-
toms of both CKD and cardiovascular disease (29,30).
Therefore, as a predisposing factor related to uremia,
hyperuricemia warrants additional attention as a potential
treatment target.Anemia. Anemia is common in HF and is associated with
increased mortality, morbidity, and worsening renal func-
tion (31). The pathogenesis of anemia in HF is multifac-
torial, encompassing hemodilution due to water retention,
blockade of normal iron transport, inflammation/cytokine-
induced erythropoietin deficiency, and tissue resistance,
malnutrition, cachexia, vitamin deficiency, all amplified in
the presence of pre-existing CKD (32,33). Reduced respon-
siveness to erythropoietin in patients with HF and CKD has
been associated with high levels of hepcidin-25, a key
regulator controlling iron intestinal absorption and distri-
bution throughout the body (34). High levels of cytokines
induce the iron-utilization defect by increasing hepcidin-25
production from the liver, which blocks the ferroportin
receptor and impairs gastrointestinal iron absorption and
iron release from macrophage and hepatocyte stores.
Hepcidin-25 may be useful in predicting erythropoietin
responsiveness in stable chronic HF patients (35). Thus,
attempts to control anemia in HF will have to take into
consideration blockade of iron transport in the body, and
attempts to overcome this problem with supplemental iron,
as well as erythropoiesis-stimulating agents such as eryth-
ropoietin and darbepoetin. Many studies of anemia in HF
with these agents and/or enteric or intravenous iron have
shown a positive effect on hospitalization rates, New York
Heart Association functional class, cardiac and renal func-
tion, quality of life, exercise capacity, and reduced B-type
natriuretic peptide levels (36,37). However, long-term ex-
posure of higher-dose erythropoiesis-stimulating agents has
been associated with higher rates of cardiovascular events,
including HF in CHOIR (Correction of Hemoglobin and
Outcomes in Renal Insufficiency) and stroke in the
TREAT (Trial to Reduce Cardiovascular Events with
Aranesp) trials (38).
Repeated episodes of subclinical AKI. It is highly prob-
able that some individuals undergo repeated episodes of
either subclinical or unrecognized episodes of AKI over the
course of a lifetime. With each episode, there is injury to
nephron units, with partial recovery of some and permanent
death to others. Because of the kidney’s ability to alter both
blood flow and filtration, the clinician would not be able to
detect these events with the measurement of serum creati-
nine (39). Such AKI events could occur with episodes of
extreme dehydration (e.g., with self-limited gastrointestinal
or viral syndromes), after elective surgeries, with toxic
therapies for other diseases (e.g., chemotherapy, antibiot-
ics), and with the use of iodinated contrast agents for a
variety of imaging studies (40). Thus, repeated subclinical
AKI in the past may explain why some individuals with
seemingly no baseline CKD or risk factors develop CRS in
the setting of ADHF.
Cardiac and Renal Fibrosis
Increased stress or injury to the myocardium, glomeruli, and
renal tubular cells, due to uncontrolled hypertension, DM,
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associated with tissue fibrosis. Responses to acute and
chronic damage can involve recruitment of immune cells,
production of cell signaling proteins from local pericytes,
mast cells, and macrophages, resulting in activation of
resident fibroblasts and myofibroblasts, and in the final
common pathway, the deposition of procollagen into the
extracellular matrix, which is irreversibly crosslinked to
collagen-generating cardiac and renal fibrosis (41).
Galectin-3 (aka MAC-2 Ag), a regulator of cardiac
fibrosis, is one of 14 mammalian galectins and is an
30-kDa glycoprotein that has a carbohydrate-recognition
binding domain of 130 amino acids that enables the
inding of beta-galactosides (42–44). It is encoded by a
ingle gene, LGALS3, located on chromosome 14, locus
21–q22 and expressed in the nucleus, cytoplasm, mito-
hondrion, cell surface, and extracellular space (45).
Galectin-3 as a paracrine signal is involved in cell adhesion,
activation, chemoattraction, growth and differentiation, cell
cycle regulation, and apoptosis in multiple diseases includ-
ing cancer, liver disease, rheumatological conditions, and
CRS (46). In the myocardium and the kidney, angiotensin
II and aldosterone are major stimuli for macrophages to
secrete galectin-3, which in turn works as a paracrine signal
on fibroblasts to help translate the signal of transforming
growth factor  (TGF) to increase cell cycle (cyclin D1)
and direct both the proliferation of pericytes and fibroblasts,
and the deposition of procollagen 1 (47). These observations
strongly suggest that fibrosis is a critical participant in the
pathogenesis and progression of CKD and HF (48). Be-
cause the tissue secretion of galectin-3 is sufficiently high, it
can be detected as a signal in blood, and thus has been
developed as a key advance for the clinical assessment of
patients at risk for CRS.
The Acute Pathways of CRS Type 1
Hemodynamics and congestion. Registry data have shown
that it is the pulmonary congestion that brings the patients
to the hospital. In the ADHERE (Acute Decompensated
Heart Failure National Registry) registry, 50% of patients
who were admitted to the hospital had a systolic blood
pressure of 140 mm Hg or higher, and only 2% had a
systolic blood pressure of90 mm Hg (49). The increase in
blood pressure is likely a reflection of sodium retention and
sympathetic activation. A dysfunctioning left ventricle is
particularly sensitive to afterload variations, and therefore,
an increase in blood pressure can abruptly worsen left
ventricular filling pressures, leading to pulmonary conges-
tion irrespective of total intravascular volume. Subsequently,
a vicious cycle arises in which cardiac remodeling leads to
functional mitral regurgitation, further increase in left atrial
pressure, and pulmonary hypertension (50). Experimental
animal data as far back as the 1930s have demonstrated that
temporary isolated elevation of central venous pressure can
be transmitted back to the renal veins, resulting in directimpairment of renal function (51). Chronic passive conges-
tion of the kidneys results in attenuated vascular reflexes
over time. As with the heart, venous congestion is one of the
most important hemodynamic determinants of CRS and
has been associated with the development of renal dysfunc-
tion in the setting of ADHF (52). However, the ESCAPE
(Evaluation Study of Congestive Heart Failure and Pulmo-
nary Artery Catheterization Effectiveness) trial found no
relationship with baseline or changes in hemodynamics on
renal outcomes (53). It is commonly observed that coexist-
ing renal dysfunction may complicate the treatment course
of HF and that the use of intravenous loop diuretics often
alleviate congestion at the cost of worsening renal function
within days of hospitalization and is a strong, independent
predictor of adverse outcomes (54). Although loop diuretics
provide prompt diuresis and relief of congestive symptoms,
they provoke a marked activation of the sympathetic and
RAAS, resulting in renovascular reflexes and sodium reten-
tion, and thus are considered a primary precipitant of CRS.
This places the patient with ADHF at risk for CRS in a
narrow therapeutic management window with respect to
fluid balance and blood pressure, as shown in Figure 3.
Neurohormonal activation. The RAAS has an important
role in the initiation and maintenance of vascular, myocar-
dial, and renal dysfunction leading to edema in HF (55).
Increased renin secretion occurs early in biventricular fail-
ure, which leads to stimulation of angiotensin II. This
8–amino acid oligopeptide has many physiological effects,
which include stimulation of central neural centers associ-
ated with increased thirst and heightened activity of gan-
glionic nerves via its effects on the autonomic nervous
system. It is a systemic vasoconstrictor to compensate for
the initial decrease in stroke volume associated with ven-
tricular failure while at the same time increasing contractil-
ity. Angiotensin II is also known to be a potent stimulator
of the sympathetic nervous system, which increases systemic
vascular resistance, venous tone, and congestion. Angioten-
sin II has direct trophic effects on cardiomyocytes and renal
tubular cells that promotes cellular hypertrophy, apoptosis,
and fibrosis (56). Angiotensin II accounts for approximately
50% of the stimulation of aldosterone release from the
adrenal gland, which increases renal sodium reabsorption
and causes sodium retention. In normal subjects, an “escape”
from renal salt-retaining effects of aldosterone usually occurs
after 3 days, thus avoiding edema formation. This aldoste-
rone escape phenomenon, however, does not occur in HF
patients, and the continued sodium retention contributes to
the pulmonary congestion and edema, particularly in those
with angiotensin-converting enzyme DD genotype (57,58).
Aldosterone stimulates macrophages in heart and kidney
tissue to secrete galectin-3, which in turn stimulates fibroblasts
to secrete procollagen I and III that is crosslinked to collagen,
resulting in fibrosis (59). Moreover, patients with biventricular
failure may also have poor hepatic perfusion and decreased
clearance of aldosterone, thereby contributing to an elevation in
the plasma aldosterone concentration (60).
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a vital role in the pathogenesis and progression of HF (61).
It is well known that elevated plasma norepinephrine levels
in patients with HF correlate with increased mortality.
Meanwhile, renal effects occur secondary to sympathetic
activation. Stimulation of adrenergic receptors on proximal
tubular cells enhances the reabsorption of sodium, whereas
adrenergic receptors in the juxtaglomerular apparatus stim-
ulate the RAAS (62).
Hypothalamic-pituitary stress reaction. Activation of
corticotrophin releasing factor neurons in the paraventricu-
lar nucleus of the hypothalamus is necessary for establishing
the classic endocrine response to stress. Stress is defined as
anything that disrupts homeostatic balance, for example,
ADHF. Any stressor that activates the hypothalamus-
pituitary-adrenal axis leads to an increase in concentrations
of the adrenal stress hormone cortisol. One of the major
hypothalamic stress hormones, which are stimulated by
different stressors including osmotic and non-osmotic stim-
uli (cytokines), is arginine vasopressin. Measurement of
circulating arginine vasopressin levels has been challenging
because it is released in a pulsatile pattern, unstable, and is
rapidly cleared from plasma. Arginine vasopressin is derived
from a larger precursor peptide (preprovasopressin) along
with copeptin, which is released from the posterior pituitary
in an equimolar ratio to arginine vasopressin and is more
stable in the circulation and closely reflects arginine vaso-
pressin levels. Copeptin levels have been found to closely
mirror the production of arginine vasopressin and have been
proposed as a prognostic marker in acute illness. Copeptin
Figure 3 Volume and Blood Pressure Management Window
Patients at risk for cardiorenal syndrome type 1 have a narrow window for manage
extremes in either parameter can be associated with worsened renal function.is elevated in several scenarios leading to CRS, includingsepsis, pneumonia, lower respiratory tract infections, stroke,
and other acute illnesses. Arginine vasopressin stimulates
the V1a receptors of the vasculature and increases systemic
ascular resistance, while stimulation of the V2 receptors in
the principal cells of the collecting duct increases water
reabsorption and leads to hyponatremia. Arginine vasopres-
sin also enhances urea transport in collecting ducts of the
nephron, thereby increasing the serum blood urea nitrogen.
The clinical consequences of these changes include sodium
and water retention, pulmonary congestion, and hyponatre-
mia, which occurs both in low-output and high-output
cardiac failure. It is important to recognize that hyponatre-
mia is a relatively late sign of arginine vasopressin over-
stimulation, and thus, earlier modulation of this system is an
important consideration in treatment. The arterial under-
filling occurs secondary to a decrease in cardiac output in
low-output HF and arterial vasodilatation in high-output
HF, both of which decrease the inhibitory effect of the
arterial stretch baroreceptors on the sympathetic and
RAAS. Thus, a vicious cycle of worsening HF and edema
formation occurs.
Inflammation and immune cell signaling. Inflammation
classically has 4 components: 1) cells; 2) cytokines; 3) antibod-
ies; and 4) complement. Thus, the term inflammation in CRS
has been termed “low-grade” or better described as an
imbalance between the immune system cell signaling path-
ways promoting and inhibiting inflammation. Over the past
30 years, there has been increasing evidence on the role of
activation of the inflammatory response in the pathogenesis
of different types of heart disease, including HF. An early
of both blood pressure and volume;mentwork of Levine et al. (63) showed that in patients with
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were much higher than normal. Numerous studies showed
activation of inflammation at various levels in HF patients.
Further support for the inflammatory etiology of HF came
from the demonstration that inflammatory cytokines may
also be produced by cardiomyocytes, following ischemic or
mechanical stimuli, but also by the innate immune response,
represented by Toll-like receptors, pentraxin-like C-reactive
protein, and pentraxin 3 (64–69). These findings suggest
that in HF, an immune dysregulation may exist; cytokines
not only could produce distant organ damage such as AKI,
but they also may play a role in further damaging myocytes.
There is evidence supporting the prognostic value of various
circulating markers of inflammation, particularly C-reactive
protein, pentraxin 3, tumor necrosis factor-alpha, IL-1, and
IL-6 (70–74).
Excessive elevations of cytokines and markers of inflam-
mation have been consistently documented in ADHF (75).
Inflammatory activation may have a role in HF by contrib-
uting to both vascular dysfunction and fluid overload in the
extravascular space (76). The amount of fluid in the pulmo-
nary interstitium and alveoli is tightly controlled by an active
process of reabsorption. Recent studies have shown that
inflammation interferes with this process and thus leads to
pulmonary fluid overload despite no increase in total body
fluid (77,78). This mechanism could be a cause for inade-
quate renal perfusion pressures, peritubular edema, patho-
logical reduction of glomerular filtration, and finally, mixed
inflammatory and ischemic tubular damage.
The role of the gut and endotoxemia. Underperfusion of
the intestine and the hematogenous release of endotoxin in
patients with HF has been proposed as a mechanism for
progression of HF and CRS type 1, particularly in patients
with cachexia (79). In HF, blood flow is presumably
shunted away from the splanchnic region, and ischemia is
particularly pronounced at the tips of the intestinal villi; in
states of intestinal underperfusion, the paracellular perme-
ability of the intestinal wall is increased as a result of
hypoxia, and local production of lipopolysaccharide and
systemic endotoxemia occurs. Disruption of intestinal func-
tion and translocation of Gram-negative bacteria or lipo-
polysaccharides as well as cytokines (tumor necrosis factor-
alpha, IL-1, and IL-6) can exacerbate myocyte dysfunction
(80). They exert their cardiosuppressive effects primarily by
altering myocardial intracellular calcium, reducing mito-
chondrial activity, causing imbalance of autonomic nerve
activity, thus affecting many other organs, including the
kidneys (81,82). When cardiomyocytes are exposed to
lipopolysaccharides, nitric oxide and cGMP are increased.
This effect is mediated by the Toll-like receptor 4 and
results in depression of excitation-depression coupling and
of the peak velocity of cardiomyocyte shortening. Further
abnormalities of cardiomyocytes have been documented, for
example, disturbed mitochondrial respiration, reduction in
resting membrane potential, Na/K gradient and im-
paired substrate metabolism, increased expression of metal- floproteinases and their inhibitors, decreased adrenergic
responsiveness, and many others. This sequence of patho-
logical events is far more evident in acutely ill patients with
sepsis, liver cirrhosis, ischemia reperfusion after burns, and
cachexia.
Superimposed infection. Superimposed infection, often
pneumonia, is a common precipitating or complicating
factor in ADHF (83). An inflammatory pathogenesis can be
a common key feature for both the kidneys and cardiovas-
cular system during sepsis, leading to cell ultrastructural
alterations and organ dysfunction. Murugan et al. (84)
recently demonstrated that AKI is associated with pneumo-
nia via an inflammatory pathogenesis. In their paper, the
outcomes of AKI were adversely associated with IL-6
plasma concentration. Proinflammatory cytokines, such as
tumor necrosis factor-alpha, IL-1, and IL-6, induce myo-
cardial dysfunction, cause microcirculatory damage, and
contribute to altered tissue perfusion and oxygen delivery/
consumption, thus contributing to both heart and kidney
failure. Enhanced endothelial expression of leukocyte adhe-
sion molecules and alteration of endothelial cell contacts can
increase microvascular permeability, thus leading to ex-
travascular fluid shift, fluid overload, hypovolemia, reduced
venous return, and lower cardiac output. Interstitial edema
further reduces oxygen delivery to tissues, and fluid overload
is an independent risk factor for mortality among septic
patients with AKI. The pathogenesis of interstitial edema
involves the glycocalyx, which is a thin (0.5 to 1.2 m)
olecular structure that lies beneath capillary endothelial
ells and regulates capillary flow, leukocyte adhesion and
igration, platelet adhesion, and coagulation. Glycocalyx
isruption due to sepsis and cytokines contributes to in-
reased permeability, both in systemic and renal microcir-
ulation, increasing leukostasis, microthrombosis, fluid shift,
nd interstitial edema.
atrogenesis. Among the mechanisms involved in organ
rosstalk between the heart and kidney, we must consider
atrogenesis (Fig. 4). In several clinical conditions, drugs
equired to treat DM, oncological diseases, infections, HF
tself, or fluid overload may affect the delicate balance
etween the heart and the kidney, leading to progressive
eterioration of both. Metformin is an antidiabetic drug
hat can result in lactic acid accumulation and worsening
eart function due to a negative inotropic effect (85,86).
hemotherapeutic agents used in solid tumor treatments
ay induce a tumor lysis syndrome, with a sudden increase
n circulating uric acid levels (87). Such an effect, although
ess dramatic, may also be induced by diuretic therapy. Uric
cid, as discussed in the preceding text, is potentially toxic to
he myocardium as well as for the tubulointerstitial compo-
ent of the kidney (88). Antibiotics may cause interstitial
ephritis and tubular dysfunction, and contribution to
rogressive renal insufficiency, especially when glomerular
ltration is stressed by a low cardiac output and activation of
he RAAS (89). Iodinated contrast causes a much different
orm of AKI characterized by transient vasoconstriction and
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contrast is taken up by proximal tubular cells and transported
into the interstitium in the kidney (90). Contrast-induced
nephropathy can be an important cause of negative feedback
on the heart with progressive worsening of cardiac disease due
to uremic complications (91). Cardiac surgery is a well-
recognized antecedent to type 1 CRS and AKI, particularly if
the patient has received contrast in the days before the
operation. Because this is one of the timed forms of AKI, there
has been considerable effort in demonstrating the novel mark-
ers of AKI (neutrophil gelatinase-associated lipocalin, kidney
injury molecule [KIM]-1, L-type fatty acid binding protein
[LFABP], N-acetyl--D-glucosaminidase [NAG], and oth-
rs) serve as both baseline risk predictors and diagnostic
ndicators of kidney damage after cardiac surgery (92,93).
Progressive salt and water retention alter intraglomerular
emodynamics and thereby influence physiological tubular-
lomerular feedback (94). Patients may already be under-
oing treatment with angiotensin-converting enzyme inhib-
tors, angiotensin II receptor blockers, direct renin inhibitors,
nd/or aldosterone blockers, all of which may negatively
mpact tubuloglomerular feedback (95). However, holding
Figure 4 Iatrogenesis and Type 1 CRS
Multiple sources of iatrogenic injury, some of which may be unavoidable, can resu
with acutely decompensated heart failure (ADHF). ACEi  angiotensin-converting e
NSAID  nonsteroidal anti-inflammatory drug.hese agents, while temporarily causing less creatinine re- dention in the blood pool, has been associated with wors-
ning of HF over the longer term (96). Combinations of
ngiotensin-converting enzyme inhibitors, angiotensin re-
eptor blockers, direct renin inhibitors, and especially aldo-
terone blockers when glomerular filtration rate is reduced
elow 45 ml/min, may lead to secondary hyperkalemia.
onsteroidal inflammatory agents reversibly inhibit cy-
looxygenases 1 and 2, impair prostaglandin synthesis, and
esult in sodium and fluid retention, as well as tissue edema,
hich consistently worsen HF outcomes (97). In the kid-
ey, edema may result in impaired oxygenation and metab-
lite diffusion, distorted tissue architecture, obstruction of
apillary blood flow and lymphatic drainage, and disturbed
ell–cell interactions that may then contribute to progres-
ive organ dysfunction (98).
The cornerstone of treatment for ADHF is the use of oral
nd intravenous loop diuretics. These agents represent a
ouble-edged sword as they may resolve congestion but
orsen renal perfusion by arterial underfilling and height-
ned activation of the sympathetic and RAAS leading to
ype 1 CRS (99).
Although registry data have demonstrated that earlier
ther cardiac, renal, or cardiorenal impairment and kidney damage in patients
inhibitor; ARB  angiotensin receptor blocker; AVP  arginine vasopressin;lt in ei
nzymeiuretic use decreases mortality in severe ADHF, there is an
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and mortality (100). Felker et al. (101), in a small random-
ized trial of ADHF, demonstrated that higher doses and
continuous infusions of furosemide resulted in more pa-
tients developing AKI (rise in creatine 0.3 mg/dl) with no
mprovement in hospitalization or death. These arguments
uggest the clinician needs better guidance on the use of
oop diuretics in ADHF. Two such sources of guidance
nclude the use of bioimpedance to estimate body water
evels as well as novel biomarkers of AKI such as neutrophil
elatinase-associated lipocalin, which rises in the setting of
iuretic-induced AKI (102).
xidative Stress:
inal Common Pathway of Injury
xidative stress is a final common pathway for cellular
ysfunction, tissue injury, and organ failure. The mecha-
isms discussed in the previous text all render both the heart
nd kidney vulnerable to loss of control over normal cellular
xidative reactions necessary for cellular function. The most
idely recognized chemical reactions generating reactive
xygen species are the Haber-Weiss and Fenton equations.
hese equations require oxygen, water, hydrogen, and a
etal catalyst in the form of iron, copper, and so on. Since
ron is the most abundant metal element in cells, it is
elieved that labile iron is the major stimulus for oxidative
tress that results in tissue injury (102). The release of poorly
iganded labile iron that remains unbound in a fraction has
een implicated in both acute ischemic cardiac models and
variety of injury models in the kidney (103–105). Impor-
antly, labile iron transitioning from Fe2 to Fe3 facilitates
he production of hydrogen peroxide and the dangerous
ydroxyl radical, which overwhelm the homeostatic antiox-
dant defense mechanisms in cells (106). Attempts to slow
hese reactions may have benefit, particularly for the kidney,
nd include alkalinization, cooling, and binding the iron
atalyst. It is important to recognize in probably every case
f CRS that oxidative stress and injury to both the heart and
idneys is playing a potentially reversible role and that these
echanisms represent a final common pathway for tissue
amage and organ failure. Thus, therapeutic attempts to
ubstantially attenuate oxidative stress, in theory, hold
romise for large benefits in patients with CRS.
ailure of Counter-Regulatory Mechanisms
he regulatory and counter-regulatory systems in ADHF
ave been studied extensively over the past several decades.
n response to wall tension, the cardiomyocyte produces
arge quantities of natriuretic peptides that work to reduce
all tension, vasodilate, and promote natriuresis and diure-
is (107). Ischemia is also recognized as a stimulus for
atriuretic peptide production. Natriuretic peptides, work-
ng via natriuretic peptide receptors in the glomerulus and
he renal tubules, activate cCMP and reduce sodium reab-
orption. When given in supraphysiological doses, B-typeatriuretic peptide reduces levels of catecholamines, angio-
ensin II, and aldosterone (108). However, this counter-
egulatory set of functions appears to be overwhelmed in
RS type 1, and thus, the patient worsens clinically and
evelops oliguria in the setting of markedly elevated levels of
atriuretic peptides.
The kidney also produces counter-regulatory proteins
hat work to reduce cellular injury. The most notable
rotein is neutrophil gelatinase-associated lipocalin, or sid-
rocalin (109). In the setting of tubular injury, unbound or
abile iron is released from the cytosol where it catalyzes the
ajor oxidative stress reactions discussed earlier in the text.
iderocalin works to mop up this poorly liganded iron and
educe oxidative stress (110,111). This is probably a vestigial
unction that also helped reduce iron availability and check
acterial growth in the setting of pyelonephritis. As with the
atriuretic peptides, this counter-regulatory protein has
een shown to be a useful diagnostic tool for AKI and is
levated in patients with CRS type 1 (112).
onclusions
RS type 1 is an important clinical phenomenon that
ccurs either de novo or in the setting of pre-existing CKD
n which the development of ADHF is complicated by
ultiple pathophysiological mechanisms. Acute cardiac and
enal congestion, neurohormonal activation, dysregulation
f immune cell and cytokine signaling, superimposed infec-
ion and anemia, and a failure of normal counter-regulatory
ystems lead to progressive and combined cardiac and renal
ysfunction. This scenario leads to multiorgan system fail-
re, drug resistance, and death in a considerable proportion
f patients. Future research exploring the mechanisms
iscussed in this paper, in particular, strategies to distin-
uish which organ is the primary initiator (type 1 versus type
CRS) will likely lead to new diagnostic and therapeutic
argets aimed to reduce the incidence and severity of this
yndrome.
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